Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 5Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × depatuxizumab mafodotin × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡